MANGALAM DRUGS & ORGANICS LTD.

Mangalam Drugs & Organics Ltd has announced the dispatch of its Annual Report for the financial year 2025-26, along with the notice convening the 53rd Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 23rd, 2026, at 03:00 PM IST, to be held via Video Conference/Other Audio-Visual Means. The report and notice are being sent electronically to shareholders. The cut-off date for e-voting is September 16, 2026, with e-voting commencing on September 19, 2026, and concluding on September 22, 2026. The Annual Report is also available on the company's website and NSDL's e-voting portal.

Mangalam Drugs & Organics Ltd has announced its 53rd Annual General Meeting (AGM) for the financial year 2025-26, scheduled for Wednesday, September 23rd, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conference/Other Audio-Visual Means. The company has also intimated the cut-off date for e-voting as September 16, 2026. The Annual Report for FY 2025-26, including the AGM notice, has been dispatched electronically to members and is available on the company's website and NSDL's e-voting portal. The filing also details changes in Key Managerial Personnel and auditors.

Mangalam Drugs and Organics Limited has officially declared a subsequent default on its loan obligations to Bank of Baroda and Bank of Maharashtra. The company has exceeded the 30-day overdue period for payments. Specifically, the default involves ₹951.19 Lacs for Bank of Maharashtra (Cash Credit A/c. No. 60383561246) and ₹606.08 Lacs for Bank of Baroda (Cash Credit A/c. No. 04170500000243). The company states it is making arrangements to pay the overdue amounts as soon as possible. This intimation follows a previous letter dated February 16, 2026.

Mangalam Drugs & Organics Ltd announced the appointment of M/s L.N. Joshi & Co. as Secretarial Auditors for a term of five years, from FY 2026-27 to 2030-31. This appointment is subject to shareholder approval at the upcoming 53rd Annual General Meeting (AGM). The Board of Directors also approved the Un-Audited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, M/s SN. Nanda & Co. was appointed as Statutory Auditors for a similar five-year term, also pending shareholder approval.

Mangalam Drugs & Organics Ltd announced the appointment of M/s S.N. Nanda & Co as Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 53rd AGM until the 58th AGM. This appointment is subject to shareholder approval at the upcoming Annual General Meeting. The Board of Directors also approved the Un-Audited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. The company declared that the statutory auditors have not expressed any modified opinions in their review reports.

Mangalam Drugs & Organics Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results. The company also declared that its statutory auditors have not expressed any modified opinions in their Limited Review Reports. Additionally, the company approved the appointment of M/s L.N. Joshi & Co. as Secretarial Auditors and M/s SN. Nanda & Co. as Statutory Auditors for a term of five years, subject to shareholder approval.

Mangalam Drugs & Organics Ltd announced that its Board of Directors, in a meeting held on August 12, 2026, approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. The company also declared that the statutory auditors have not expressed any modified opinions in their Limited Review Reports. Additionally, the board approved the appointment of M/s L.N. Joshi & Co. as Secretarial Auditors and M/s SN. Nanda & Co. as Statutory Auditors for a five-year term, subject to shareholder approval.

Mangalam Drugs & Organics Ltd has announced the resignation of its Secretarial Auditor, M/s. Ragini Chokshi & Co. (FRN: 92897). The resignation is effective from August 4, 2026. The firm cited pre-occupancy with professional commitments and other unavoidable reasons as the cause for stepping down. The company has enclosed the resignation letter and provided details as required by SEBI regulations. Shweta Patel, Company Secretary, signed the intimation.

Mangalam Drugs & Organics Ltd has announced a Board of Directors meeting scheduled for August 12, 2026. The primary agenda is to consider and approve the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. Additionally, the board will discuss the appointment of M/s L.N. Joshi & Co. as Secretarial Auditors for five years and M/s S.N. Nanda & Co. as Statutory Auditors. The trading window for dealing in the company's securities has been closed from July 1, 2026, until 48 hours after the announcement of the Q1 FY27 results.

Mangalam Drugs & Organics Ltd has filed an intimation regarding a subsequent default on its bank loan obligations. The company has defaulted on loan accounts with Bank of Maharashtra and Bank of Baroda for a period exceeding 30 days. The overdue amount for Bank of Maharashtra is ₹951.19 Lacs, with the default starting on October 17, 2025. For Bank of Baroda, the overdue amount is ₹606.08 Lacs, with the default commencing on October 20, 2025. The company states it is making arrangements to pay the overdue amounts as soon as possible.